Regulation. Enforcement. AI adoption in biopharma.
Every quarter. Sourced from public record. Provenance-linked.
ANGIS Intelligence is a quarterly brief covering regulatory signals, enforcement actions, and the state of AI adoption across biopharma — generated from the same governed corpus that powers Innovate and Inspect, delivered as a certified evidence artifact.
Choose your level of access.
Every subscriber receives a certified, provenance-linked brief. Annual subscribers receive two months free and priority early access the day each brief is signed.
- Full Q1 2026 brief, delivered by email
- Certified evidence artifact with public verification URL
- Early notice of future ANGIS releases
- Rolling access to every new quarterly brief
- Complete archive of past briefs
- Subscriber-only research notes between releases
- Priority delivery and signed verification links
We'll email you the full Q1 2026 brief. No charge, no obligation.
The current brief.
FDA Enforcement Trends in Clinical Trial AI Governance
Released: Q1 2026 · Annapolis, MD
A quarter-by-quarter read of FDA enforcement posture on AI-generated evidence in clinical trial submissions, warning letter trends, and the governance language now appearing in refuse-to-file actions. Sourced entirely from public record and provenance-linked to each cited document.
Read the previewEvery brief is generated through the same governed pipeline that underlies Innovate and Inspect. Each claim is linked to its source, each source is classified and timestamped, and each brief is cryptographically signed and chained to the full governance record.
Future quarters will cover global regulatory convergence, payer and reimbursement signals around AI-generated evidence, and the intersection of AI governance with the emerging enforcement environment across drug development, devices, and digital health.
A governed corpus. Not a content mill.
ANGIS Intelligence is generated from a governed knowledge graph of regulatory documents, enforcement records, clinical trial registrations, and published literature — all classified, timestamped, and continuously updated under the same proprietary governed pipeline architecture that produces Innovate and Inspect outputs. Every claim in every brief traces back to a signed source; every brief is itself a certified evidence artifact.